• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

女性氯胺酮使用者的尿症状和生活质量受损:停止使用后的持续存在。

Urinary symptoms and impaired quality of life in female ketamine users: persistence after cessation of use.

机构信息

Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong.

出版信息

Hong Kong Med J. 2011 Aug;17(4):267-73.

PMID:21813893
Abstract

OBJECTIVE

To compare the urinary symptoms and quality of life in ex-ketamine abusers and controls.

DESIGN

Prospective observational study.

SETTING

A hospital in Hong Kong.

PATIENTS

Female ex-ketamine abusers admitted to a local drug rehabilitation centre and age-matched controls attending a general gynaecology clinic between December 2009 and April 2010.

MAIN OUTCOME MEASURES

Evaluation of urinary symptoms based on a 3-day bladder diary, and responses to the Urogenital Distress Inventory Short Form (UDI-6) and the Incontinence Impact Questionnaire Short Form (IIQ-7). The study group had repeat measurements 3 months later.

RESULTS

Overall, 90% of ex-ketamine abusers had active urinary symptoms. On average, they had increased 24-hour urinary frequency (10.0 vs 5.8; P=0.001) and lower maximum voided volume (253.3 mL vs 401.9 mL; P<0.001) compared to controls. Correspondingly, the median functional bladder capacity was smaller (195.3 mL vs 261.2 mL; P=0.011) and the mean UDI-6 and IIQ-7 scores were higher (P<0.001). Among those who abused ketamine for 2 years or more, the mean UDI-6 and IIQ-7 scores were higher (P=0.03, P=0.02 respectively). When they stopped abusing ketamine for 3 months or more, their mean 24-hour urinary frequency had decreased (P=0.03), the maximum voided volume had increased (P=0.03) and the mean UDI-6 and IIQ-7 scores had decreased (P=0.04, P=0.02 respectively), although they were still higher than in controls. After 3 more months, in the ex-ketamine abusers there had been a further decrease in 24-hour urinary frequency (P=0.01) and a further improvement in quality of life based on mean UDI-6 scores (P=0.04) but nevertheless poorer than the control group (P<0.01).

CONCLUSION

Female ex-ketamine abusers had significant urinary symptoms affecting their quality of life when studied at a mean of 8 (range, 0.5-48) months after cessation of use. The symptom severity was inversely correlated with the duration of cessation; though they improved with time, some still persisted.

摘要

目的

比较氯胺酮滥用者和对照组的尿症状和生活质量。

设计

前瞻性观察研究。

地点

香港一家医院。

患者

2009 年 12 月至 2010 年 4 月期间,被收治于当地戒毒中心的女性氯胺酮滥用者和在普通妇科诊所就诊的年龄匹配的对照组。

主要观察指标

根据 3 天膀胱日记评估尿症状,以及对尿生殖窘迫量表(UDI-6)和尿失禁影响问卷短表(IIQ-7)的反应。研究组在 3 个月后进行了重复测量。

结果

总体而言,90%的氯胺酮滥用者有活跃的尿症状。与对照组相比,他们的平均 24 小时排尿频率增加(10.0 比 5.8;P=0.001),最大排尿量减少(253.3 毫升比 401.9 毫升;P<0.001)。相应地,中位功能性膀胱容量更小(195.3 毫升比 261.2 毫升;P=0.011),UDI-6 和 IIQ-7 的平均评分更高(P<0.001)。在滥用氯胺酮 2 年或以上的人群中,UDI-6 和 IIQ-7 的平均评分更高(P=0.03,P=0.02)。当他们停止滥用氯胺酮 3 个月或以上时,他们的平均 24 小时排尿频率下降(P=0.03),最大排尿量增加(P=0.03),UDI-6 和 IIQ-7 的平均评分下降(P=0.04,P=0.02),尽管仍高于对照组。3 个月后,在氯胺酮滥用者中,24 小时排尿频率进一步下降(P=0.01),基于 UDI-6 评分的生活质量进一步改善(P=0.04),但仍差于对照组(P<0.01)。

结论

在停止使用氯胺酮平均 8(范围 0.5-48)个月后进行研究时,女性氯胺酮滥用者的尿症状明显影响其生活质量。症状严重程度与停止使用的时间呈反比;尽管随着时间的推移有所改善,但有些仍持续存在。

相似文献

1
Urinary symptoms and impaired quality of life in female ketamine users: persistence after cessation of use.女性氯胺酮使用者的尿症状和生活质量受损:停止使用后的持续存在。
Hong Kong Med J. 2011 Aug;17(4):267-73.
2
Persistence of urinary symptoms after cessation of ketamine abuse.氯胺酮滥用停止后泌尿症状的持续存在。
Hong Kong Med J. 2011 Aug;17(4):260.
3
Moxifloxacin relieves the persistent symptoms of lower urinary tract after cessation of ketamine abuse.莫西沙星可缓解氯胺酮滥用戒断后下尿路的持续症状。
Hong Kong Med J. 2011 Dec;17(6):515.
4
One-stop clinic for ketamine-associated uropathy: report on service delivery model, patients' characteristics and non-invasive investigations at baseline by a cross-sectional study in a prospective cohort of 318 teenagers and young adults.一站式诊所治疗氯胺酮相关性尿路病:一项前瞻性队列研究中 318 名青少年和年轻成人的横断面研究报告服务提供模式、患者特征和基线时的非侵入性检查结果。
BJU Int. 2014 Nov;114(5):754-60. doi: 10.1111/bju.12675.
5
The Chinese version of the pelvic pain and urgency/frequency symptom scale: a useful assessment tool for street-ketamine abusers with lower urinary tract symptoms.中文版盆腔疼痛和急迫/频繁症状量表:评估街头使用氯胺酮的下尿路症状患者的有用工具。
Hong Kong Med J. 2012 Apr;18(2):123-30.
6
Validation of the Urogenital Distress Inventory (UDI-6) and Incontinence Impact Questionnaire (IIQ-7) in a Dutch population.泌尿生殖系统困扰量表(UDI - 6)和尿失禁影响问卷(IIQ - 7)在荷兰人群中的验证。
Neurourol Urodyn. 2015 Jan;34(1):24-31. doi: 10.1002/nau.22496. Epub 2013 Oct 26.
7
[Validation of the Spanish version of the short forms of the Urogenital Distress Inventory (UDI-6) and the Incontinence Impact Questionnaire (IIQ-7) in pregnant women].[《泌尿生殖系统困扰量表简表(UDI-6)和尿失禁影响问卷(IIQ-7)西班牙语版本在孕妇中的效度验证》]
Gac Sanit. 2011 Sep-Oct;25(5):379-84. doi: 10.1016/j.gaceta.2011.05.010. Epub 2011 Aug 25.
8
Cognitive impairments in poly-drug ketamine users.多药滥用氯胺酮使用者的认知障碍。
Addict Behav. 2013 Nov;38(11):2661-6. doi: 10.1016/j.addbeh.2013.06.017. Epub 2013 Jun 28.
9
Long-term patient satisfaction following cadaveric pubovaginal sling incontinence surgery using the UDI and IIQ-7 questionnaires.使用UDI和IIQ-7问卷评估尸体耻骨后阴道吊带术治疗尿失禁的长期患者满意度。
Neurourol Urodyn. 2007;26(2):185-9. doi: 10.1002/nau.20318.
10
Validation of the short forms of the incontinence impact questionnaire (IIQ-7) and the urogenital distress inventory (UDI-6) in a Turkish population.尿失禁影响问卷简表(IIQ - 7)和泌尿生殖系统困扰量表(UDI - 6)在土耳其人群中的效度验证
Neurourol Urodyn. 2007;26(1):129-33. doi: 10.1002/nau.20292.

引用本文的文献

1
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment.创伤后应激障碍治疗的迷幻未来。
Curr Neuropharmacol. 2024;22(4):636-735. doi: 10.2174/1570159X22666231027111147.
2
Clinical and behavior characteristics of individuals who used ketamine.使用氯胺酮的个体的临床和行为特征。
Sci Rep. 2022 Jan 17;12(1):801. doi: 10.1038/s41598-022-04832-9.
3
Prevention and Management of Common Adverse Effects of Ketamine and Esketamine in Patients with Mood Disorders.预防和管理心境障碍患者使用氯胺酮和 Esketamine 的常见不良反应。
CNS Drugs. 2021 Sep;35(9):925-934. doi: 10.1007/s40263-021-00846-5. Epub 2021 Aug 7.
4
A pilot study of urine cytokines in ketamine-associated lower urinary tract symptoms.氯胺酮相关下尿路症状中尿细胞因子的一项初步研究。
Int Urogynecol J. 2014 Dec;25(12):1715-9. doi: 10.1007/s00192-014-2451-5. Epub 2014 Jun 28.
5
Ketamine for chronic pain: risks and benefits.氯胺酮治疗慢性疼痛:风险与获益。
Br J Clin Pharmacol. 2014 Feb;77(2):357-67. doi: 10.1111/bcp.12094.